



D1
contd




and




29. (Twice Amended) A composition comprising 6β, 7β; 15β, 16β-dimethylene-3-oxo-

17α-pregn-4-ene-21,17-carbolactone, a pharmaceutically acceptable carrier, and less than 0.2% by weight of said compound of the contaminants

D2




and



wherein X is an anion of an acid which is effective to open said 6 β , 7 β -methylene group.

3. 10. (Amended) A composition comprising

(a) 6 β , 7 β ; 15 β , 16 β -dimethylene-3-oxo-17 α -pregn-4-ene-21,17-carbolactone made by a process comprising dehydrating a compound of Formula III,




which was made by oxidizing in the presence of a ruthenium salt a compound of Formula

II,


II,

*102
Control*



II



which was made by catalytically hydrogenating a compound of Formula I



I

- (b) a pharmaceutically acceptable carrier, and
- (c) less than 0.2% by weight of said compound (a) of the byproducts of said preparation process which are

D. J. Condit



wherein X is an anion of an acid which is effective to open said 6 β , 7 β -methylene group.


3

Please add new claims 13 and 14 as follows:

5

--13. 6 β , 7 β ; 15 β , 16 β -dimethylene-5 β -hydroxy-3-oxo-17 α -androstane-21,17-

carbolactone




in isolated form.

6

14. 6 β , 7 β ; 15 β , 16 β -dimethylene-5 β -hydroxy-3-oxo-17 α -androstane-21,17-

carbolactone



in isolated and purified form.--